Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations
{{output}}
Melanoma today is considered as a spectrum of melanocytic malignancies characterised by clinical and molecular features, including targetable mutations in several kinases such as BRAF or c-KIT. The successful development of therapies targeting these mutations ... ...
